Compare VIPS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | PTGX |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.4B |
| IPO Year | 2012 | 2016 |
| Metric | VIPS | PTGX |
|---|---|---|
| Price | $14.38 | $101.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $19.58 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 2.2M | 430.0K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $3.79 | $874.25 |
| Revenue Next Year | $2.05 | N/A |
| P/E Ratio | ★ $9.00 | $2,040.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.36 | $46.16 |
| 52 Week High | $21.08 | $107.84 |
| Indicator | VIPS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 51.92 |
| Support Level | $14.08 | $96.36 |
| Resistance Level | $15.23 | $106.85 |
| Average True Range (ATR) | 0.48 | 4.14 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 45.34 | 59.51 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.